<?xml version="1.0" encoding="UTF-8"?>
<ref id="R45">
 <label>45.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Moreno</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Greil</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Demirkan</surname>
    <given-names>F</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial</article-title>. 
  <source>
   <italic toggle="yes">Lancet Oncol.</italic>
  </source>
  <year>2019</year>;
  <volume>20</volume>:
  <fpage>43</fpage>â€“
  <lpage>56</lpage>.
  <pub-id pub-id-type="pmid">30522969</pub-id>
 </mixed-citation>
</ref>
